In the Claims

Claims 1-25 (canceled)

26. (currently amended) A method of treating pain, drug addiction, or tinnitus in a mammal, comprising the step of orally administering to a mammal in need thereof an effective amount of a formulation, wherein said formulation comprises [[comprising]] a beta-cyclodextrin or gamma-cyclodextrin; and a compound represented by A:

$$\begin{pmatrix} R_{3} & \begin{pmatrix} C \\ Y \end{pmatrix} & N \\ R_{6} & R_{1} \end{pmatrix}$$

$$\begin{pmatrix} R_{6}R_{5}C \end{pmatrix}_{m}$$

$$R_{4}$$

wherein

m is 0, 1, 2, 3 or 4;

y is 0;

R<sub>1</sub> represents aryl or heteroaryl;

R<sub>2</sub> represents H, alkyl, or cycloalkyl;

R<sub>3</sub> represents H, alkyl, aryl, heteroaryl, CH<sub>2</sub>OR<sub>2</sub>, or CO<sub>2</sub>R<sub>2</sub>;

R<sub>4</sub> represents aryl;

R<sub>5</sub> represents independently for each occurrence H, alkyl, or cycloalkyl;

R<sub>6</sub> represents independently for each occurrence H, alkyl, or cycloalkyl;

any two geminal or vicinal instances of  $R_5$  and  $R_6$  may be connected through a covalent bond; and

the stereochemical configuration at any stereocenter of a compound represented by A is R, S, or a mixture of these configurations.

- 27. (original) The method of claim 26, wherein said mammal is a primate, equine, canine or feline.
- 28. (original) The method claim 26, wherein said mammal is a human.
- 29. (canceled)
- 30. (new) The method of claim 26, 27, or 28, wherein said beta-cyclodextrin or gamma-cyclodextrin is hydroxypropyl-beta-cyclodextrin or hydroxypropyl-gamma-cyclodextrin.